Effect of TyG Index on Outcomes of Radical Prostatectomy (TyG-PCa)

February 24, 2018 updated by: Mustafa Ozan HORSANALI, Recep Tayyip Erdogan University Training and Research Hospital

A Novel Prognostic Risk Factor for Patients Undergoing Radical Prostatectomy: Triglyseride-Glucose (TyG) Index

We investigate the association between Triglyserid-Glucose(TyG) index and prostate cancer in patients undergoing radical prostatectomy.

Study Overview

Status

Completed

Conditions

Detailed Description

TyG index is calculated with special formula. Patients undergoing radical prostatectomy are divided two groups according to the cut-off level of 8.55 for TyG index.Groups were compared statistically in terms of oncological outcomes and survival.

Study Type

Observational

Enrollment (Actual)

200

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

patients undergoing radical prostatectomy for prostate cancer between january 2007 and december 2012.

Description

Inclusion Criteria:

  • Patients undergoing radical prostatectomy for prostate cancer

Exclusion Criteria:

  • taking medicines for established diabetes and dyslipidaemia,
  • presence of endocrinological disease,
  • history of bariatric surgery,
  • missing data and patients with uncontrolled follow-up

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oncological outcomes
Time Frame: 5 years
Effect of TyG index on oncological outcomes of Prostate cancer
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Survival
Time Frame: 5 years
Death date of patient after radical prostatectomy
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Recep Tayyip Erdogan University Training and Research Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2007

Primary Completion (Actual)

December 30, 2012

Study Completion (Actual)

December 30, 2012

Study Registration Dates

First Submitted

February 20, 2018

First Submitted That Met QC Criteria

February 24, 2018

First Posted (Actual)

February 27, 2018

Study Record Updates

Last Update Posted (Actual)

February 27, 2018

Last Update Submitted That Met QC Criteria

February 24, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Recepteutrh

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Syndrome

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe